75N95020Q00208

Submitted by pluggern on
Post Date/ Solicitation Issue Date
Closing Response Date
Proposed Award Date
Project Title
Testing of compounds against the AKT1 and LATS1 compounds in a NanoBRET target Engagement Intracellular Kinase Assay
Contracting Office
National Center for Advancing Translational Sciences (NCATS)

Contact Points

Primary Contract Specialist

Kimberly
Espinosa
kimberly.espinosa@nih.gov
NAICS Code Number
541380
Single-Sole Source Determination
Non-Competitive (Single-Sole Source (including Brand Name)) Determination: The Government intends to award a purchase order on a non-competitive basis to Reaction Biology Corporation, 1 Great Valley Pkwy, Ste 2, Malvern, PA 19355-1423. The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted that identified no other sources of supply or service capable of achieving this Government requirement. The data obtained through these assays will be compared to data obtained through previous assays. To allow a direct comparison between this data, and to ensure the continuity of science, the required service is available only from Reaction Biology Corporation.
Background/Description of Requirement

The National Center for Advancing Translational Sciences (NCATS) is a translational science center that prides itself on its tremendously productive pipeline and is innovative in a number of ways. NCATS brings together a diverse range of scientists, including medicinal chemists, biologists, toxicologists, and engineers, in order to ultimately translate basic science into real products and services that help improve people’s lives. Included in this process is the development of unique small molecules as potential anticancer agents.

The kinases LATS1 and AKT are of interest to NCATS, especially in terms of the cellular inhibition of these enzymes. The objective of this requisition is to test 20 compounds against these kinases in a cellular NanoBret assay, in order to determine their relative inhibition of the relevant enzymes. This testing will inform on kinase inhibitory activity in our compound series, and will facilitate further optimization and development of these AKT1 / LATS1 compounds as well as potential treatments.

This requirement is for the following:

Line Item 1: Testing of 20 compounds against the AKT1 and LATS1 compounds in a NanoBRET target Engagement Intracellular Kinase Assay. 

This includes:

1. Performing experiments using the NanoBRET Target Engagement Intracellular Kinase Assay platform testing each of 20 compounds for inhibitory activity against the AKT1 and LATS1 compounds.
2. Providing a comprehensive report for each batch, that includes the results of the experiments of each of the 10 compounds in that batch against AKT1 and LATS1.
3. Receiving two batches of 10 compounds each from the Government.

The period of performance is one (1) year, to begin on or shortly after the date of award.

Interested parties may identify in writing their interest and capability in response to this requirement. Responses to this notice shall contain sufficient information to establish the interested parties’ bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.

All responses must be received by closing date and must reference the announcement. Responses may be submitted electronically to the attention of the contract specialist. Fax responses will not be accepted.

All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency.